Jon Congleton - 09 Feb 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLYS
Reported as of: 09 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2023, 20:01:45 UTC
Next SEC filing: 21 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 13 Feb 2023.

Key facts

This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2023, 20:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +250,046
Change %
Price: $0.000000
Shares after: 250,046
Date: 09 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,046
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.